middle.news
Prescient Therapeutics Targets $7 Million SPP to Propel PTX-100 Development
9:06am on Tuesday 25th of August, 2026 AEST
•
Healthcare
Read Story
Prescient Therapeutics Targets $7 Million SPP to Propel PTX-100 Development
9:06am on Tuesday 25th of August, 2026 AEST
Key Points
SPP priced at $0.065 per share, 18.8% discount to 10-day VWAP
Funds to advance PTX-100 past Dose Optimisation Committee in H2 2026
SPP open to eligible shareholders with $30,000 maximum participation
Potential follow-on placement to sophisticated investors post-SPP
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE